Navigation Links
$52.5 Million Settlement Against Sepracor Inc. Approved
Date:9/10/2007

Berger & Montague and Wolf Haldenstein Obtain Third-Largest Settlement in Securities Fraud Case Against Bio-Tech Company on Drug Approval

PHILADELPHIA, Sept. 10 /PRNewswire-USNewswire/ -- Judge Morris E. Lasker of the U.S. District Court for the District of Massachusetts has granted final approval of a $52.5 million settlement in two separate but related securities class actions against Sepracor Inc., a Massachusetts-based pharmaceutical company (Nasdaq: SEPR). The lawsuits arose from Sepracor's alleged concealment of safety concerns surrounding its new antihistamine candidate, Soltara, that was rejected by the FDA for marketing approval in March 2002. The settlement is the third-largest settlement in a securities fraud case against a bio-technology company concerning a drug approval.

The suit was maintained by Staro Asset Management, LLC on behalf of a debt class consisting of holders of Sepracor's convertible debt securities, and by Westmont Venture Partners, LLC on behalf of an equity class consisting of holders of Sepracor's common stock, call options and put options.

The two classes were represented by a team of attorneys from Berger & Montague, P.C. of Philadelphia; and Wolf Haldenstein Adler Freeman & Herz, LLP, New York, led by Sherrie R. Savett of Berger & Montague and Daniel W. Krasner of Wolf Haldenstein. Berger & Montague shareholder Gary E. Cantor and associate Joshua C. Schumacher, and Wolf Haldenstein partner David L. Wales and associate Stacey T. Kelly were also heavily involved in the prosecution of this action.

A preliminary settlement agreement was reached between the parties in April 2007 after nearly five years of litigation. Lead plaintiff's attorney for the debt class, Sherrie R. Savett of Berger & Montague, noted that "the settlement is excellent for the classes. If we had gone to trial, there would have been a battle of conflicting medical and scientific experts given the multitude of complex scientific issues surrounding the development of Sepracor's new drug candidate. Additionally, economic experts would have quarreled about the proper measure of damages to the two classes caused by Sepracor's failure to obtain approval for its highly touted antihistamine drug."

This settlement is the second announced within the last week by Berger & Montague. On September 4, the firm announced a settlement valued at $67-$80 million against the Philadelphia Stock Exchange, its CEO and six investment firms.

Investors who purchased any of the affected Sepracor securities during the class period May 17, 1999 -- March 6, 2002, or who have questions concerning the settlement, should contact

(bondholders) Berger & Montague at 888-891-2289 or InvestorProtect@bm.net; (shareholders) Wolf Haldenstein at 212-545-4600, or Wales@whafh.com; Skelly@whafh.com

Berger & Montague, founded in 1970, is a pioneer in class action litigation. The firm's 67 attorneys concentrate their practice in complex litigation including securities and investor fraud, antitrust, civil and human rights, consumer protection and environmental and mass torts, and have recovered several billion dollars for consumers and investors.

For more information:

Joshua C. Schumacher, Berger & Montague, P.C., 215 875-3055 jschumacher@bm.net


'/>"/>
SOURCE Berger & Montague, P.C.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Drug May Make Breathing Easier for Millions
2. Hundred million dollar gift for malaria institute
3. George Bush pledges 200 million dollars for AIDS relief
4. Over Six Million HIV Infected People In South Africa- Finds A Survey
5. Hope for 11 million children facing death from illnesses
6. The forgotten epidemic killing millions
7. WHO and UNAIDS unveil plan to get 3 million AIDS patients on treatment by 2005
8. Tanzanian Government Sanctions $20 Million For AIDS Arug
9. Grant of $7 million for Orissa Medical College from Japan
10. Merck to pay $ 253.5 million to Vioxx victim family
11. GlaxoSmithKline to Supply United States with 8 Million flu vaccine, Fluarix
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... 2017 , ... Tuesday, March 28, 2017, is the annual American Diabetes Association ... Test to find out if they are at risk for developing Type 2 diabetes. ... evening sky by programming the LAX pylons the color red. Downtown’s U.S. Bank Tower ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... team. Ruel Williamson brings his extensive knowledge of appraisals, property values, ad valorem ... the real estate valuation industry for more than 40 years. , “Ruel is ...
(Date:3/28/2017)... ... 2017 , ... The Thyroid Secret is a specialized 9-part ... program was recently launched on March 1, and Dr. Wentz discussed varied benefits ... Dr. Izabella Wentz is a licensed pharmacist and a foremost thyroid specialist. After ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... software and services, is proud to announce it has joined the National Association ... representing the interests of chronically ill, disabled, and dying Americans of all ages ...
(Date:3/28/2017)... ... March 28, 2017 , ... Alert Sentry Group LLC., ... (Mobile Personal Emergency Response Systems), the iSAFE and the iSAFE Plus. These iSAFE products ... first of their kind, the iSAFE and iSAFE Plus offer direct GPS Location and ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... March 29, 2017  NuVasive, Inc. (NASDAQ: NUVA), ... spine surgery with minimally disruptive, procedurally-integrated solutions, today ... clearance of the CoRoent® Small Interbody™ System indicated ... in the cervical spine. This marks the first ... used at up to four contiguous levels. ...
(Date:3/29/2017)... , March 29, 2017 NetworkNewsWire ... ... the public safety in regulating marijuana, but economic arguments also ... creation, and reduced law enforcement costs. However, to legalize and ... provided by SinglePoint, Inc. (OTC: SING) ( SING Profile ), ...
(Date:3/29/2017)... - Medicure Inc. ("Medicure") (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical ... ended December 31, 2016 after market close on ... released later than the previous fiscal year,s results ... and balances of Apicore from the acquisition date ... date meets TSX Venture Exchange listed company requirements. ...
Breaking Medicine Technology: